



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Clopidogrel Krka d.d.

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0036/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	24/11/2023	09/02/2024	SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0035	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	09/06/2022	29/06/2023	SmPC and PL	
IB/0034	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	23/11/2021	16/12/2021	SmPC and PL	
IA/0033	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	12/11/2021	n/a		
IB/0032	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	30/04/2021	19/05/2021	SmPC and PL	

	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0031	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	08/12/2020	19/05/2021	SmPC and PL	
IB/0029	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	25/02/2020	14/05/2020	SmPC and PL	
IB/0028	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	25/09/2019	14/05/2020	SmPC, Annex II, Labelling and PL	
IB/0027/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	05/06/2019	14/05/2020	SmPC, Labelling and PL	

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0026	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	17/04/2018	03/05/2019	SmPC, Labelling and PL	
IA/0025/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	16/04/2018	n/a		
IB/0024/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	22/05/2017	06/07/2017	SmPC, Labelling and PL	

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0023/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	08/12/2015	20/05/2016	SmPC, Annex II and PL	

IB/0022	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	28/05/2015	20/05/2016	SmPC and PL	
PSUSA/820/201311	Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel	10/07/2014	n/a		PRAC Recommendation - maintenance
R/0018	Renewal of the marketing authorisation.	20/03/2014	03/06/2014		The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. The MAH has submitted an Addendum to Clinical Overview (ACO) to provide details of the efficacy and safety of Clopidogrel Krka d.d. since its approval. In the CHMP's view the provided data do not change the overall knowledge about the beneficial effect and safety profile of clopidogrel when used in the approved indications. The beneficial effect of Clopidogrel Krka d.d. remains in line with that of the originator product (Plavix), and is considered positive.
IB/0021/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a	24/04/2014	10/06/2015	SmPC and PL	

	generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0019	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	18/01/2014	03/06/2014	SmPC	
IB/0016/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	19/12/2013	n/a		
IB/0017/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	28/10/2013	03/06/2014	SmPC	

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0015/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	23/09/2013	03/06/2014	SmPC, Annex II, Labelling and PL	
IB/0012	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	07/09/2012	n/a		
IB/0011/G	This was an application for a group of variations.	07/03/2012	n/a	SmPC and PL	

	A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size				
IB/0010	B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation	02/03/2012	12/09/2012	SmPC and PL	
IB/0009	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	06/12/2011	21/03/2012	SmPC and Labelling	
IB/0008/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	27/10/2011	21/03/2012	SmPC and PL	

	product - Implementation of change(s) for which NO new additional data are submitted by the MAH				
IA/0007	A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs	18/05/2011	n/a	SmPC, Annex II, Labelling and PL	
IB/0004/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	28/04/2011	n/a	SmPC, Annex II and PL	To update sections 4.2 "Posology and method of administration", 4.4 "Special warnings and precautions for use", 4.5 "Interaction with other medicinal products and other forms of interaction" and 5.2 "Pharmacokinetic properties" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3). Package Leaflet has been updated accordingly. Furthermore indications have been added in the SPC as only one indication was available at date of authorizations due to patent reasons. Now the full indications as for the reference product are being added. No new data is submitted as the SPC of the reference product (Plavix) is being followed. Package Leaflet has been updated accordingly. All changes in Summary of product characteristics and

					Package Leaflet are performed only due to harmonisation with the Reference Medicinal Product Information. Additionally we add List of local representatives and we also updated Annex II with regards to Pharmacovigilance system according to the procedural announcement from October and November 2010.
IA/0005	A.7 - Administrative change - Deletion of manufacturing sites	27/04/2011	n/a		
T/0003	Transfer of Marketing Authorisation	17/02/2011	14/04/2011	SmPC, Labelling and PL	
IB/0002	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	06/08/2010	n/a	SmPC and PL	
IB/0001	IB_18_Replacement of an excipient with a comparable excipient	23/12/2009	n/a	SmPC and PL	